Literature DB >> 28899059

Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.

Tanner M Johanns1,2, Jay A Bowman-Kirigin3,4, Connor Liu3,4, Gavin P Dunn2,4,5.   

Abstract

Entities:  

Year:  2017        PMID： 28899059      PMCID： PMC6287409          DOI： 10.1093/neuros/nyx321

Source DB:  PubMed          Journal:  Neurosurgery        ISSN： 0148-396X            Impact factor:   4.654


× No keyword cloud information.
  111 in total

1.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Authors:  Valsamo Anagnostou; Kellie N Smith; Patrick M Forde; Noushin Niknafs; Rohit Bhattacharya; James White; Theresa Zhang; Vilmos Adleff; Jillian Phallen; Neha Wali; Carolyn Hruban; Violeta B Guthrie; Kristen Rodgers; Jarushka Naidoo; Hyunseok Kang; William Sharfman; Christos Georgiades; Franco Verde; Peter Illei; Qing Kay Li; Edward Gabrielson; Malcolm V Brock; Cynthia A Zahnow; Stephen B Baylin; Robert B Scharpf; Julie R Brahmer; Rachel Karchin; Drew M Pardoll; Victor E Velculescu
Journal:  Cancer Discov       Date:  2016-12-28       Impact factor: 39.397

4.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

5.  Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.

Authors:  Maria Parkhurst; Alena Gros; Anna Pasetto; Todd Prickett; Jessica S Crystal; Paul Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

Review 6.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.

Authors:  Gavin P Dunn; Ian F Dunn; William T Curry
Journal:  Cancer Immun       Date:  2007-08-13

7.  Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Authors:  Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Orsolya Rajky; Gerda Ricken; Adelheid Wöhrer; Karin Dieckmann; Martin Filipits; Anita Brandstetter; Michael Weller; Sebastian Kurscheid; Monika E Hegi; Christoph C Zielinski; Christine Marosi; Johannes A Hainfellner; Matthias Preusser; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2014-10-29       Impact factor: 12.300

8.  Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.

Authors:  Jenette Creaney; Shaokang Ma; Sophie A Sneddon; Michelle R Tourigny; Ian M Dick; Justine S Leon; Andrea Khong; Scott A Fisher; Richard A Lake; W Joost Lesterhuis; Anna K Nowak; Shay Leary; Mark W Watson; Bruce W Robinson
Journal:  Oncoimmunology       Date:  2015-05-11       Impact factor: 8.110

9.  Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Authors:  Yong-Chen Lu; Xin Yao; Jessica S Crystal; Yong F Li; Mona El-Gamil; Colin Gross; Lindy Davis; Mark E Dudley; James C Yang; Yardena Samuels; Steven A Rosenberg; Paul F Robbins
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

10.  Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.

Authors:  S Han; C Zhang; Q Li; J Dong; Y Liu; Y Huang; T Jiang; A Wu
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640
View more
  11 in total

Review 1.  Effective effectors: How T cells access and infiltrate the central nervous system.

Authors:  Kendra L Congdon; Luis A Sanchez-Perez; John H Sampson
Journal:  Pharmacol Ther       Date:  2018-12-14       Impact factor: 12.310

Review 2.  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

Authors:  Gavin P Dunn; Timothy F Cloughesy; Marcela V Maus; Robert M Prins; David A Reardon; Adam M Sonabend
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

3.  Cell Membrane-Coated Magnetic Nanocubes with a Homotypic Targeting Ability Increase Intracellular Temperature due to ROS Scavenging and Act as a Versatile Theranostic System for Glioblastoma Multiforme.

Authors:  Christos Tapeinos; Francesca Tomatis; Matteo Battaglini; Aitor Larrañaga; Attilio Marino; Iker Aguirrezabal Telleria; Makis Angelakeris; Doriana Debellis; Filippo Drago; Francesca Brero; Paolo Arosio; Alessandro Lascialfari; Andrea Petretto; Edoardo Sinibaldi; Gianni Ciofani
Journal:  Adv Healthc Mater       Date:  2019-08-07       Impact factor: 9.933

Review 4.  A review of glioblastoma immunotherapy.

Authors:  Ravi Medikonda; Gavin Dunn; Maryam Rahman; Peter Fecci; Michael Lim
Journal:  J Neurooncol       Date:  2020-04-06       Impact factor: 4.130

Review 5.  Immunotherapy Against Gliomas: is the Breakthrough Near?

Authors:  Rimas V Lukas; Derek A Wainwright; Craig M Horbinski; Fabio M Iwamoto; Adam M Sonabend
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

6.  Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma.

Authors:  Tanner M Johanns; Christopher A Miller; Connor J Liu; Richard J Perrin; Diane Bender; Dale K Kobayashi; Jian L Campian; Michael R Chicoine; Ralph G Dacey; Jiayi Huang; Edward F Fritsch; William E Gillanders; Maxim N Artyomov; Elaine R Mardis; Robert D Schreiber; Gavin P Dunn
Journal:  Oncoimmunology       Date:  2019-01-25       Impact factor: 8.110

Review 7.  Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.

Authors:  Pavlina Chuntova; Kira M Downey; Bindu Hegde; Neil D Almeida; Hideho Okada
Journal:  Front Immunol       Date:  2019-01-22       Impact factor: 7.561

Review 8.  Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma.

Authors:  Kirit Singh; Kelly M Hotchkiss; Kisha K Patel; Daniel S Wilkinson; Aditya A Mohan; Sarah L Cook; John H Sampson
Journal:  Cancers (Basel)       Date:  2021-10-26       Impact factor: 6.639

Review 9.  Receptor-Targeted Glial Brain Tumor Therapies.

Authors:  Puja Sharma; Waldemar Debinski
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923

10.  A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.

Authors:  Montserrat Lara-Velazquez; Jack M Shireman; Eric J Lehrer; Kelsey M Bowman; Henry Ruiz-Garcia; Mitchell J Paukner; Richard J Chappell; Mahua Dey
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.